FundedIQ
Health Care

Versantis: Funding, Investors & Team (Sep 2026)

Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.

www.versantis.ch LinkedIn Zürich, Switzerland 11-50 employees
Health Care Health Diagnostics Pharmaceutical Therapeutics
Total raised
$500k
Rounds
1
Latest
Grant
Apr 2022

Versantis has raised $500k across 1 funding round on record, the most recent a Grant of $500k announced in Apr 2022.

That round is below the $4.8M median round size for Health Care companies tracked on FundedIQ over the last two years.

Versantis Company Profile and Key Stats

Total funding raised
$500k
across 1 round on record
Funding rounds on record
1
Latest funding round
Grant
$500k in Apr 2022
Employees
11-50
reported band
Headquarters
Zürich, Switzerland

Latest funding round on record: Apr 2022.

Versantis Funding Rounds

Date
Round
Amount
Grant
$500k

Versantis Founders and Leadership Team

Name
Role
Contact
Vincent Forster
CEO
Locked

Contact details for the Versantis team: 1 of 1 has an email address on file.

Start 14-day free trial →

Versantis Funding Compared to Other Health Care Startups

Segment
Companies
Median round
3,653
$4.8M
881
$3.8M
1,065

Versantis' latest round of $500k is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Versantis in Health Care and Zürich

Companies Similar to Versantis

MoleSense is to provide a wearable skin sensor to help monitor high-risk pregnancies.

Undisclosed round $110k

CeQur Simplicity helps people with diabetes by developing drug-delivery devices. They develop bolus insulin…

Series E $100M

Calmea develops advanced contactless sensing systems that invisibly track sleep and automatically modify…

Undisclosed round $190k

NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for…

Series B $33.6M

UNBOOUND is a medtech company and university spin-off (The Rockefeller University and University of Geneva)…

Undisclosed round $130k

Christina Vallgren and Marcus Palm, two physicists from CERN, co-founded Terapet along with Professor Raymond…

Undisclosed round $2.6M
Seed

Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of…

Undisclosed round $6.0M

Babylat is an enricher device is the first automated, small-scale tabletop device for the protein enrichment…

Undisclosed round $1.0M

Altiscreen is creating and producing cutting-edge, portable drug-of-abuse detection systems. With the use of…

Undisclosed round $150k

Vivent provides growers, breeders and agrochem companies with actionable information direct from plants…

Undisclosed round $8.7M

Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded…

Undisclosed round $4.5M

Versantis Funding FAQs

What does Versantis do?

Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.

How much funding has Versantis raised?

Versantis has raised $500k across 1 round on record. The most recent is a Grant of $500k announced in Apr 2022.

When did Versantis last raise funding?

Versantis' most recent funding round on record is a Grant of $500k, announced in Apr 2022.

Who is the CEO of Versantis?

Vincent Forster is listed as CEO at Versantis.

Where is Versantis headquartered?

Versantis is based in Zürich, Zurich, Switzerland.

How many employees does Versantis have?

Versantis is in the 11-50 employee band.

How does Versantis' funding compare to other Health Care startups?

Versantis' latest round of $500k is below the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.

About FundedIQ's Versantis Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Versantis is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.